Heart failure (HF) represents a significant global health challenge, characterized by a variety
of symptoms resulting from cardiac dysfunction. This dysfunction often leads to systemic and …

Heart failure (HF) represents a significant global health challenge, characterized by high
morbidity and mortality rates, and imposes considerable burdens on healthcare systems and …

Biomarker testing in patients with heart failure (HF) is rapidly expanding. With high-quality
research indicating its diagnostic and prognostic capabilities, biomarkers are excellent …

Despite the enhanced knowledge of the pathophysiology of heart failure (HF), it still remains
a serious syndrome with substantial morbidity, mortality, and frequent hospitalizations …

Cardiovascular disease (CVD) is a serious public health concern whose incidence has been
on a rise and is projected by the World Health Organization to be the leading global cause of …

Heart failure (HF) is a complex syndrome with an enormous societal burden in terms of cost,
morbidity, and mortality. Natriuretic peptide testing is now widely used to support diagnosis …

Heart failure (HF) may be considered as the fatal finishing line of all cardiovascular
disorders. Despite advances in the understanding and treatment, it still has a poor …

Early detection and risk stratification of patients with heart failure (HF) are crucial to improve
outcomes. Given the complexity of the pathophysiological processes of HF and the …

Heart failure is a complex disease in which a careful clinical examination and the
measurement of cardiac function may not always be sufficient for making a correct …

The last decade has seen exciting advances in the field of biomarkers used in managing
patients with heart failure (HF). Biomarker research has broadened our knowledge base …